We have shown that ACE2 activator, DIZE, given orally for 16 weeks, was able to stabilize atherosclerotic lesions and attenuate hepatic steatosis in apoE−/− mice fed an HFD. This evidence concerns the gene ACE2 and fatty liver disease.